Drug induced central sleep apnea

Summary

Drug induced central sleep apnea (MONDO:0024357) is a disease. A subtype of central sleep apnea syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	drug induced central sleep apnea
Mondo ID	MONDO:0024357
SNOMED CT	104831000119109
UMLS	C3662033
MedGen	783188
Is cancer (heuristic)	no

Also known as: drug induced central sleep apnea

Disease family

This is a subtype of central sleep apnea syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › central sleep apnea syndrome › drug induced central sleep apnea

Related subtypes (4): primary central sleep apnea syndrome, complex sleep apnea, central sleep apnea due to periodic breathing, central sleep apnea caused by high altitude

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.